Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRURISCOPE nemolizumab study in atopic dermatitis
jRCT1031260456Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Maximum itch visual analogue scale response during peripheral nerve testing and von Frey filament testing, Area under the curve of itch VAS stimulus-intensity curve and 8 more. Started Sep 2026; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT1031260456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260456.